Products & Services

iCell® Hepatocytes

Investigate Liver Disease with Human Hepatocytes

The medical community needs a reproducible, well-characterized, and readily available source of human hepatocytes to advance significantly the launch of new metabolic and infectious disease therapies, reduce the incidence of drug-induced liver injury, and accelerate the development of novel approaches to liver regeneration and transplantation.

To meet this need, CDI has leveraged iPS cell technology  to develop iCell® Hepatocytes. These hepatocytes overcome the functionality, reproducibility, and availably limitations of existing primary cell and tumor-derived cell models by providing the following:

  • Relevant hepatic functionality and phenotypic stability
  • Expression of clinical targets that are relevant for liver and metabolic disease
  • Compatibility with a wide range of 3D and microphysiological systems
  • Quality-controlled manufacturing and batch reproducibility
  • Ready supply in a cryopreserved format

Two Types to Choose From

Cellular Dynamics offers 2 terminally differentiated hepatocyte products: iCell Hepatocytes and iCell Hepatocytes 2.0. While the original iCell Hepatocytes enable a shorter workflow in a more matured product at thaw, iCell Hepatocytes 2.0 do not require Matrigel in culture and have some functional advantages in vitro. Please inquire for additional guidance on the product that best meets your specific application.


iCell Hepatocytes

iCell Hepatocytes 2.0

Albumin Expression

Upon thawing

After 5 days of culture

CYP activity

48 hours

7-10 days

Time to assay

24 Hours post thaw

7 days post thaw

Viability in culture

14-21 days

21-28 days

Matrigel in Culture


Not Required

Proven Applications

iCell Hepatocytes are being rapidly adopted for use in a wide range of applications:

  • Diabetes research and drug discovery
    Functional insulin and glucose regulation pathways and a flexible product format enable high-throughput screening for novel drug candidates
  • Hepatotoxicity assessment
    Known genetic background and proven ability to detect metabolism-dependent and immune-mediated hepatotoxicity provide confidence in safety testing without the need for time-consuming and costly lot testing (See Sirenko, et al. 2013, Mann, 2014, Lu, et al 2015)
  • Liver tissue engineering
    Compatibility with bioengineered scaffold engraftment, organ recellularization, and 3D printing enable new clinical and regenerative medicine strategies (See Berger, et al. 2015, Ware, et al. 2015)
  • Ordering Information
    Catalog # Description Quantity
    HCC-100-010-001 iCell Hepatocytes

    Cryopreserved iCell Hepatocytes

    >9 x 106
    Viable Cells/Vial
    Request Quote
    PHC-100-020-001 iCell Hepatocytes 2.0 Kit

    Each kit contains:

    • Cryopreserved iCell Hepatocytes
    • 3 ml iCell Hepatocytes Medium Supplement
    >9 x 106
    Viable Cells/Vial
    Request Quote